NASDAQ · Biotechnology

CRVS (CRVS) Stock

$13.31 +3.02% NASDAQ: CRVS Healthcare

Valuation

MetricValue
Price$13.31
Market Cap$1.12B
P/E Ratio-23.00
P/B Ratio16.80
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$26.95
52-Week Low$3.55
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-24.59%
ROA-21.13%
ROCE-70.49%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio6.44

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-39.0M$-33.0M$-23.0M$-28.0M$-43.0M
Net Profit$-43.0M$-41.0M$-27.0M$-62.0M$-15.0M
EPS$-1.03$-0.89$-0.56$-1.02$-0.53
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$109.0M$68.0M$46.0M$69.0M$71.0M
Total Liabilities$12.0M$12.0M$7.0M$36.0M$10.0M
Cash$63.0M$13.0M$13.0M$9.0M$5.0M
Borrowings$4.0M$3.0M$1.0M$1.0M$1.0M

Latest News

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? Motley Fool · Jun 23, 2026 Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest Simply Wall St. · Jun 14, 2026 Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? Insider Monkey · Jun 13, 2026 Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China GlobeNewswire · Jun 9, 2026 Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million Motley Fool · May 24, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-37.0M$-27.0M$-24.0M$-25.0M$-33.0M
Investing Cash Flow$22.0M$-24.0M$16.0M$-27.0M$-8.0M
Financing Cash Flow$1.0M$0$0$33.0M$0
Net Cash Flow$47.0M$-50.0M$-1.0M$-4.0M$-4.0M
Free Cash Flow$-37.0M$-27.0M$-24.0M$-25.0M$-33.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-3.26%
Quick Ratio19.81
Interest Coverage—
Return 1Y192.93%
Return 3Y465.29%
Return 5Y542.49%

Ownership

Insiders Held3.51%
Institutions Held85.57%
Institutions Float Held88.68%
Institutional HolderSharesReport Date
Orbimed Advisors LLC.7,165,0062026-03-31
Blackrock Inc.6,160,4222026-03-31
State Street Corporation3,565,9922026-03-31
Adams Street Partners, LLC3,275,6162026-03-31
Vanguard Capital Management LLC3,234,5382026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABSI $7.13 -5.69% -11.32 $1.21B 0.00%
AKBA $1.31 -0.76% -45.00 $351.42M 0.00%
CMPX $1.89 -4.55% -4.71 $340.37M 0.00%
GOSSGossamer Bio, Inc. $0.19 +38.24% -0.17 $44.10M 0.00%
KALV $27.00 +0.00% -8.28 $1.44B 0.00%

About CRVS

CRVS is led by CEO Richard A. Miller, employs 31 people, headquartered in US, publicly traded since 2016.

CRVS stock trades at $13.31 with a market capitalization of $1.12B. The stock is valued at a price-to-earnings (P/E) ratio of -23.00, price-to-book of 16.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.55 and $26.95, and currently trades 50.6% below its 52-week high.

On profitability, CRVS generates a return on equity (ROE) of -24.59%, return on capital employed of -70.49%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides